By Bhanvi Satija and Christy Santhosh (Reuters) -Shares of Sarepta Therapeutics slumped as much as 49.4% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy,

Sarepta Therapeutics Inc. plummeted in early trading after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.